Management ChangeMay 21, 2026, 04:13 PM
Ironwood Appoints Interim CFO; Grants 25,000 RSUs
AI Summary
Ironwood Pharmaceuticals Inc. announced the appointment of Mr. Silver as the company's interim chief financial officer and principal financial officer, effective May 19, 2026. In connection with this new role, the Committee approved a monthly interim assignment fee of $12,250 for Mr. Silver. Additionally, Mr. Silver received a grant of 25,000 restricted stock units, which will vest over two years.
Key Highlights
- Mr. Silver appointed as interim chief financial officer and principal financial officer.
- Approved a monthly interim assignment fee of $12,250 for Mr. Silver.
- Mr. Silver received a grant of 25,000 restricted stock units (RSUs).
- RSUs will vest over two years, with 50% vesting on each approximate anniversary of the grant date.
Price Impact
More from IRWD